Modern Clinical Research on LSD
Neuropsychopharmacology April 27, 2017 DOI: 10.1038/npp.2017.86 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Intervention | LSD |
| Dose | two doses |
| Duration | 2 months follow-up |
| Topics | Anxiety LSD |
| Keywords | Hallucinogen Dissociative |
| Citations | 230 |
| Key findings | LSD produces a range of subjective, physiological, and neural effects mediated by the 5-HT2A receptor, and two doses reduced anxiety for 2 months in patients with life-threatening disease. |
Abstract
All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of LSD were mediated by the 5-HT2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility. LSD impaired the recognition of sad and fearful faces, reduced left amygdala reactivity to fearful faces, and enhanced emotional empathy. LSD increased the emotional response to music and the meaning of music. LSD acutely produced deficits in sensorimotor gating, similar to observations in schizophrenia. LSD had weak autonomic stimulant effects and elevated plasma cortisol, prolactin, and oxytocin levels. Resting-state functional magnetic resonance studies showed that LSD acutely reduced the integrity of functional brain networks and increased connectivity between networks that normally are more dissociated. LSD increased functional thalamocortical connectivity and functional connectivity of the primary visual cortex with other brain areas. The latter effect was correlated with subjective hallucinations. LSD acutely induced global increases in brain entropy that were associated with greater trait openness 14 days later. In patients with anxiety associated with life-threatening disease, anxiety was reduced for 2 months after two doses of LSD. In medical settings, no complications of LSD administration were observed. These data should contribute to further investigations of the therapeutic potential of LSD in psychiatry.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Reviews modern LSD research and reports that two LSD doses reduced anxiety for 2 months in patients with life-threatening disease.
Synthesized
Comparable studies
Other narrative reviews on LSD for anxiety, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ayahuasca: Pharmacology, neuroscience and therapeutic potential | 2016 | Review | |
| Psychedelic Drugs in Biomedicine | 2017 | Review | |
| Studies on Lysergic Acid Diethylamide (LSD-25) Nonpsychotic subjects | 1956 | Review | |
| The Past and Future of Psychedelic Science: An Introduction to This Issue | 2019 | Review | |
| Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD) | 2018 | Review |
Citations in the library
Cited by 158
- Global Street Food: la cocina de la calle Diseño interior 2009
- Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology February 2, 2022
- Long-term effects of psychedelic drugs: A systematic review Neuroscience & Biobehavioral Reviews March 16, 2020
- Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics Frontiers in Psychiatry September 10, 2021
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
and 153 more in the library
Cites 76
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs Frontiers in Human Neuroscience 2014
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
and 71 more in the library